Literature DB >> 31005950

Effect of metformin on clinical and biochemical hyperandrogenism in adolescent girls with type 1 diabetes.

Mona Hafez1, Noha Musa2, Shaimaa Elbehairy1, Sahar Abdel Atty3, Menna Elbarbary4, Maha Amin1.   

Abstract

Background Hyperandrogenism with or without polycystic ovarian syndrome is seen in adolescents with type 1 diabetes (T1D), especially those with suboptimal control. Objective To assess the effect of metformin on hyperandrogenism and ovarian function in adolescents with T1D. Methods This prospective study included 28 T1D females showing signs of hyperandrogenism. History taking (detailed diabetes history and menstrual history) and anthropometric measurements (weight, height, body mass index [BMI], waist and hip circumference) were initially performed, and then the patients were assessed for the manifestations of hyperandrogenism (acne, hirsutism as well as pelvic ultrasound [U/S] for ovarian morphology). Biochemical evaluation for ovulation (progesterone assessment during the luteal phase), sex steroids (estradiol, testosterone, dehydroepiandrosterone sulfate [DHEAS] and androstenedione), prolactin, glycemic control (hemoglobin A1c [HbA1c]) and gonadotropin levels (follicle stimulating hormone [FSH] and luteinizing hormone [LH]) was done. Patients were subjected to 500 mg metformin twice daily orally for 1 year, and then the patients were re-evaluated for clinical and biochemical parameters. Results Metformin therapy resulted in a significant reduction in weight (p = 0.001), BMI (p = 0.002), acne (p = 0.008), hirsutism score (0.007), LH (p = 0.008), testosterone (p < 0.001) and androstenedione levels (p = 0.028) in adolescent girls with T1D. Regarding menstrual irregularities, there was a significant reduction in the number of patients with oligomenorrhea (68%) with a p value of <0.001. However, there were no significant reduction in the daily insulin requirements (p = 0.782) or HbA1c (p = 0.068). Nausea and/or abdominal pain were the commonly reported side effects of metformin (64%). Conclusions Metformin as an insulin sensitizing agent improved the BMI and cycle regularity together with clinical and biochemical hyperandrogenism in T1D adolescent girls. However, it did not improve their glycemic control.

Entities:  

Keywords:  adolescent girls; hyperandrogenism; metformin; polycystic ovary syndrome; type 1 diabetes

Mesh:

Substances:

Year:  2019        PMID: 31005950     DOI: 10.1515/jpem-2018-0430

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  2 in total

Review 1.  Resistance to the Insulin and Elevated Level of Androgen: A Major Cause of Polycystic Ovary Syndrome.

Authors:  Haigang Ding; Juan Zhang; Feng Zhang; Songou Zhang; Xiaozhen Chen; Wenqing Liang; Qiong Xie
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-20       Impact factor: 5.555

2.  Metformin Therapy for Acne in Patients with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis.

Authors:  Hsuan Yen; Yu-Tung Chang; Fui-Jun Yee; Yu-Chen Huang
Journal:  Am J Clin Dermatol       Date:  2021-01       Impact factor: 7.403

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.